Progesterone: When to Order This Test

What Progesterone Measures and Why It Matters

Progesterone is a steroid hormone produced primarily by the corpus luteum after ovulation, by the placenta during pregnancy, and in smaller quantities by the adrenal glands. A serum progesterone test quantifies circulating levels in nanograms per milliliter (ng/mL) and serves as a direct biomarker of ovulatory function and luteal adequacy.

The Endocrine Society's 2017 clinical practice guideline on female infertility identifies mid-luteal serum progesterone as the single most practical biochemical marker of ovulation [1]. Unlike basal body temperature charting or urinary LH kits, a blood draw provides a quantitative result that clinicians can compare against established cutoffs. The American Society for Reproductive Medicine (ASRM) reinforces this, noting that a mid-luteal progesterone level above 3 ng/mL "provides reliable evidence that ovulation has occurred" [2]. This threshold is not arbitrary. It was derived from studies correlating serum progesterone with ultrasound-confirmed follicular rupture, where sensitivity exceeded 90% at the 3 ng/mL cutoff [3].

Progesterone also plays a direct role in endometrial receptivity. Without sufficient progesterone during the secretory phase, the endometrial lining does not mature enough to support embryo implantation. That biological reality makes this lab test relevant far beyond a simple yes-or-no ovulation check.

Primary Indications: When Your Clinician Should Order the Test

A progesterone draw is indicated in five well-defined clinical scenarios. The test is not a screening tool for the general population. It answers a specific clinical question each time it is ordered.

Ovulation confirmation in infertility workup. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 217 recommends serum progesterone measurement as a first-line test during the evaluation of infertility [4]. For couples who have not conceived after 12 months of unprotected intercourse (or 6 months if the female partner is over 35), confirming that ovulation actually occurs is the logical starting point. A value above 3 ng/mL, drawn 7 days before the expected next period, confirms it.

Luteal phase deficiency assessment. When a patient ovulates but progesterone remains below 10 ng/mL mid-luteal, clinicians suspect luteal phase deficiency (LPD). The ASRM's 2021 committee opinion noted that while LPD remains a debated diagnosis, low mid-luteal progesterone is the most commonly used biochemical criterion [2].

Early pregnancy viability. First-trimester progesterone below 5 ng/mL is associated with a nonviable pregnancy in over 85% of cases, according to a meta-analysis of 26 studies (N = 9,436) published in Human Reproduction Update [5]. Clinicians order the test alongside serial beta-hCG when ectopic pregnancy or early miscarriage is suspected.

HRT monitoring. The 2022 North American Menopause Society (NAMS) position statement recommends monitoring progesterone in women receiving cyclic or continuous combined HRT to verify that the progestogen component is providing adequate endometrial protection [6]. This is particularly relevant for patients using micronized progesterone (Prometrium), where absorption varies between oral and vaginal routes.

Congenital adrenal hyperplasia (CAH) follow-up. Elevated 17-hydroxyprogesterone is the primary screening marker for CAH, but baseline progesterone measurement helps monitor treatment adequacy in patients on glucocorticoid replacement [7].

Timing the Draw: Why Day 21 Is a Guideline, Not a Rule

The "day 21 progesterone test" is one of the most commonly cited lab timing recommendations in reproductive endocrinology. It is also one of the most commonly misapplied.

Day 21 assumes a textbook 28-day cycle with ovulation on day 14. Many women do not ovulate on day 14. A woman with a 35-day cycle likely ovulates around day 21, which means her mid-luteal peak falls near day 28. Drawing on day 21 of a 35-day cycle captures the early luteal phase, producing a misleadingly low value that could trigger unnecessary interventions.

The correct approach: count backward. The luteal phase is relatively fixed at 12 to 14 days. Subtract 14 from the total cycle length to estimate ovulation day, then add 7. For a 32-day cycle, that means drawing on approximately day 25 [1]. The Endocrine Society guideline explicitly states that "progesterone should be measured in the mid-luteal phase, timed according to the individual patient's cycle length" [1].

For patients with irregular cycles where predicting the draw date is impractical, serial progesterone measurements every 2 to 3 days starting around day 18 can capture the peak. Alternatively, clinicians can use urinary LH kits to detect the LH surge, then schedule the blood draw 7 days later.

Fasting is not required. Time of day has minimal impact on results, although progesterone is secreted in pulses with amplitude variation of 2 to 3 ng/mL over a few hours [8]. A single mid-luteal draw remains the standard, but awareness of pulsatile secretion helps explain why two draws taken hours apart on the same day might differ modestly.

Normal Progesterone Ranges by Phase and Context

Interpreting a progesterone result requires knowing where in the cycle (or pregnancy, or life stage) the patient sits at the time of the draw. A value of 8 ng/mL is reassuringly normal mid-luteal, possibly concerning in early pregnancy, and abnormally high in a postmenopausal patient not on HRT.

Follicular phase: <1.0 ng/mL. Progesterone stays suppressed before ovulation. A value above 1.5 ng/mL during the follicular phase may indicate premature luteinization and can compromise IVF cycle outcomes [9].

Mid-luteal phase: 5 to 20 ng/mL in most reference laboratories. The ASRM uses a threshold of 3 ng/mL to confirm ovulation occurred, but values above 10 ng/mL are associated with better endometrial receptivity and higher pregnancy rates in natural conception cycles [2].

First trimester pregnancy: 10 to 44 ng/mL, rising progressively. A prospective cohort study of 1,435 pregnancies published in Fertility and Sterility found that first-trimester progesterone below 12 ng/mL carried a 4.7-fold increased risk of miscarriage compared with levels above 20 ng/mL [10].

Second and third trimester: 20 to 150+ ng/mL. The placenta takes over production from the corpus luteum by approximately weeks 8 to 10, and levels rise steadily through delivery.

Postmenopausal (no HRT): <0.5 ng/mL. Values above this warrant investigation for an ovarian or adrenal source.

Males: 0.1 to 0.2 ng/mL. Progesterone is a precursor in the testosterone synthesis pathway. In men on TRT, suppressed gonadotropins can lower progesterone further, though this is rarely clinically significant.

Dr. Nanette Santoro, Professor of Obstetrics and Gynecology at the University of Colorado School of Medicine and past president of the American Society for Reproductive Medicine, has noted: "A single progesterone value is a snapshot. The clinical picture, the cycle day, and the patient's history tell you what that snapshot means" [11].

What High Progesterone Means

Elevated progesterone outside of pregnancy or the luteal phase raises a focused differential diagnosis. The most common explanations are iatrogenic (supplementation or HRT), ovarian cysts with continued corpus luteum function, and rarely, hormone-secreting tumors.

In IVF cycles, premature progesterone elevation above 1.5 ng/mL on the day of trigger has been associated with lower live-birth rates. A 2019 meta-analysis of 60,000 IVF cycles found a 10% relative reduction in ongoing pregnancy rates when trigger-day progesterone exceeded 1.5 ng/mL [9]. This finding changed clinical practice: many reproductive endocrinologists now monitor progesterone on trigger day and consider freeze-all strategies when levels are elevated.

Congenital adrenal hyperplasia (non-classic form) can present with mildly elevated progesterone alongside elevated 17-hydroxyprogesterone. The Endocrine Society's CAH guideline recommends a stimulated 17-OHP test for definitive diagnosis, but a baseline progesterone above 2 ng/mL in the follicular phase adds supporting evidence [7].

Ovarian hyperstimulation syndrome (OHSS) may also produce supraphysiologic progesterone levels from multiple corpora lutea. In the ASRM-sponsored OHSS prevention guideline, progesterone monitoring is recommended alongside estradiol to track response to gonadotropin stimulation [12].

What Low Progesterone Means and How to Raise It

Low mid-luteal progesterone (below 10 ng/mL with confirmed ovulation) is the biochemical hallmark of luteal phase deficiency. The clinical consequences include difficulty achieving pregnancy, early pregnancy loss, and irregular or shortened cycles.

Causes of low progesterone include anovulation (the most common), hypothalamic amenorrhea from energy deficit or stress, hyperprolactinemia, thyroid dysfunction, and age-related decline in corpus luteum quality. Polycystic ovary syndrome (PCOS) may paradoxically produce either anovulation with absent progesterone or irregular ovulation with suboptimal luteal function [13].

Progesterone supplementation is the direct pharmacologic intervention. ACOG recommends vaginal progesterone (90 mg Crinone gel or 200 mg micronized progesterone insert) for luteal phase support in IVF cycles, based on data from the LOTUS I and LOTUS II trials [14]. For non-IVF patients with recurrent pregnancy loss attributed to low progesterone, the PRISM trial (N = 4,153) published in the New England Journal of Medicine found that vaginal micronized progesterone 400 mg twice daily increased live-birth rates from 69.9% to 72.5% (adjusted rate ratio 1.03, 95% CI 1.00 to 1.07), a modest but statistically meaningful benefit in the subgroup with prior bleeding and three or more previous losses [15].

Lifestyle factors that support endogenous progesterone production include maintaining a healthy body weight (both extremes of BMI suppress ovulation), managing chronic stress (cortisol and progesterone share the pregnenolone precursor pathway), and ensuring adequate vitamin B6 intake, which one small study associated with higher luteal progesterone [16]. These are adjuncts, not replacements for medical therapy when progesterone is clinically low.

Clomiphene citrate or letrozole can indirectly raise progesterone by inducing a stronger ovulation with a more strong corpus luteum. The Endocrine Society recommends letrozole as first-line ovulation induction for PCOS, citing the NICHD trial (N = 750), where letrozole produced higher ovulation and live-birth rates than clomiphene [1] [17].

How to Lower Progesterone When Levels Are Too High

True progesterone excess that requires lowering is uncommon outside of iatrogenic overreplacement. The most frequent clinical scenario involves a patient on HRT whose micronized progesterone dose produces side effects (drowsiness, bloating, mood changes) while maintaining progesterone levels well above the target for endometrial protection.

For HRT patients, the 2022 NAMS position statement notes that the minimum effective dose of micronized progesterone for endometrial protection is 100 mg daily in continuous regimens or 200 mg daily for 12 to 14 days per month in cyclic regimens [6]. Reducing to these minimums while monitoring for breakthrough bleeding is the standard approach.

For premature progesterone elevation in IVF cycles, the intervention is not lowering the hormone itself but adjusting the stimulation protocol. Dr. Richard Scott, Laboratory Director at RWJMS-IVI and founding partner of Reproductive Medicine Associates of New Jersey, has stated: "The clinical significance of premature progesterone rise is about the endometrium, not the oocyte. A freeze-all strategy effectively removes the endometrial impact from the equation" [18]. Reducing gonadotropin dose, using GnRH-antagonist protocols, or switching to a freeze-all cycle are the evidence-based responses.

In rare cases of progesterone-secreting ovarian tumors, surgical resection is definitive. These are almost always identified on imaging before progesterone-lowering becomes the clinical focus.

Progesterone Testing in Men on TRT

Progesterone is rarely ordered for male patients, but it has clinical relevance in specific situations. In men receiving testosterone replacement therapy, endogenous gonadotropin suppression reduces testicular and adrenal steroid precursors, including progesterone. The clinical significance is minimal in most cases.

Where progesterone measurement matters in men: suspected congenital adrenal hyperplasia (elevated progesterone accompanies elevated 17-OHP), evaluation of gynecomastia (progesterone can contribute to breast tissue stimulation), and monitoring of men using compounded "progesterone cream" marketed for sleep or hair loss [19]. The American Urological Association's 2018 testosterone guideline does not include progesterone in routine TRT monitoring panels, but notes that a complete steroid hormone evaluation may be warranted when clinical presentation is atypical [20].

Ordering the Test: Practical Logistics

Serum progesterone is a standard immunoassay available at every major reference laboratory. No fasting is required. No special preparation is needed. The sample is a standard serum tube (SST or red-top), and results are typically available within 24 to 48 hours.

Cost without insurance ranges from $25 to $75 at most commercial laboratories. Many direct-to-consumer lab services offer progesterone as part of fertility or hormone panels at comparable pricing.

Repeat testing is appropriate when the initial result is ambiguous (3 to 5 ng/mL mid-luteal), when cycle timing is uncertain, or when monitoring response to supplementation. In IVF monitoring, progesterone may be drawn every 2 to 3 days during the stimulation phase.

Salivary progesterone is marketed as a convenient alternative, but the Endocrine Society's 2019 position statement on hormone testing explicitly recommends serum over saliva for clinical decision-making, citing poor standardization across salivary assays and significant variability with hydration status and collection technique [21]. Salivary testing may have a role in research settings but should not guide treatment decisions.

Patients using topical progesterone cream should inform their clinician before testing. Transdermal progesterone can produce disproportionately high salivary levels while serum levels remain low, a dissociation that complicates interpretation if the wrong sample type is collected [6].